Why TheranosticTrials.org?

The leading global platform for radiopharmaceutical & molecular imaging clinical trials

Global Reach

We are uniquely positioned at the heart of Theranostics.

Increasing Awareness

We're dedicated to increasing awareness about Theranostics and it's potential.

Fostering Engagement

We encourage active participation in the Theranostics community.

Building Connections

We connect physicians, clinics, and patients with Theranostic opportunities.

Comprehensive Resources

Access a complete list of cancer Theranostic Trials and educational materials.

Advancing the Field

We collaborate with key opinion leaders to push Theranostics forward.

Our Ultimate Goal

Provide more hope to cancer patients everywhere!


Navigating Tips

Pick Your Path


Stats

Theranostic Research Report

Source: Oppenheimer & Co. Research

View All


Isotopes

View details about the isotopes used in the trials listed on our site!

Learn more
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s

DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Scott Tagawa, MD

Scott T. Tagawa, MD, MS, FASCO, FACP is a Professor of Medicine and Professor of Medicine in Urology at Weill Cornell Medicine, and an Attending Physician at NewYork-Presbyterian – Weill Cornell Medical Center. After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. Following completion of his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. He had the opportunity to train with international leaders in Genitourinary (GU) Oncology. In 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medical College in 2007. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, bladder, and kidney cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development in GU malignancies with a particular interest cell-surface targeting, including prostate-specific membrane antigen (PSMA) theranostics. Dr. Tagawa serves as co-Leader of the Cancer Therapeutics Program and Leader of the GU Disease Management Team of the Meyer Cancer Center. He is the WCM principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. He has served on multiple committees for the American Society of Clinical Oncology and has been awarded Fellowship in ASCO. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple “top doctor” award lists.

Read More
See All Investigators

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.

View RLT Components

Education


banana

Sponsors

urotodayblueearthdiagnosticsltdadvancedacceleratorapplicationsbayertelixpharmaceuticalsfusionpharmaceuticalsincclaritypharmaceuticalscuriumpointbiopharmaratiotherapeuticsincartbionorthstarnucleusradiopharmaradiopharmtheranosticsprostatecancerfoundationinvenraconvergenttherapeuticsterrapowerisotopesnusanorlsradiopharmacies

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468